Targets › CD8B
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. (UniProt, P10966)
Open in Phaseline: the race on CD8B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Zirconium Zr 89-Df-Crefmirlimab Anti-CD8 positron emission tomography imaging agent | CD8A, CD8B | Phase 1 | Metastatic Malignant Solid Neoplasm | Oct 2027 |
Metastatic Malignant Solid Neoplasm (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.